Anergis Files Provisional U.S. Patent on AllerDM Dust Mite Allergy Treatment
6/13/2013 9:01:20 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
June 13th, 2013 -- EPALINGES, Switzerland - Anergis, a company focusing on proprietary synthetic allergy vaccines designed to provide ultra-fast desensitization, has filed for provisional patent protection of its AllerDM dust mite allergy treatment in the U.S. The company plans to extend the patent application within the next 12 months to achieve world-wide protection under the Patent Cooperation Treaty.
AllerDM is an allergy vaccine for patients with house dust mite allergy and is based on Anergis' proprietary Contiguous Overlapping Peptide (COP) technology, which allows for ultra-fast desensitization in only two months treatment. COP allergy vaccines are pharmaceutical quality products, which have proven to be safe and well tolerated and to induce a long-term immune effect. AllerDM is currently in pre-clinical development and is expected to enter clinical stage in 2015. Further details on the product are not being disclosed at present.
House dust mites are the most frequent cause of allergy and suspected to trigger severe consecutive disorders. Asthma may be caused by house dust mite allergy in 50 to 80% of patients. It is estimated that about 60 million patients in Europe, 30 million in the U.S., 20 million in Japan and 60 million in China suffer from dust mite allergies.
"Defining COPs for this important new indication illustrates once again the ability of our technology platform to generate products against a broad range of allergies," said Christophe Reymond, CSO of Anergis. "We are planning to continue discovering, developing and patenting further innovative COP allergy vaccines in the future."
"In parallel to our AllerT Phase IIb efficacy trial in patients allergic to birch pollen, we are very pleased to have been able to discover and initiate the development of two more products addressing high unmet medical needs," said Vincent Charlon, CEO of Anergis. "This provides us with fascinating development perspectives."
AllerT, the lead product of Anergis, is currently evaluated in a double-blind, randomized, placebo-controlled Phase IIb trial in 240 patients with moderate to severe birch pollen allergy, enrolled at 24 trial centers throughout Europe. Results are expected in Q3, 2013.
Earlier this year, Anergis presented preclinical data of its ragweed allergy vaccine candidate AllerR. A Phase I/IIa trial of AllerR is expected to start in 2015.
Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines targeting commercially attractive indications. Anergis´ vaccines are based on its IP-protected Continuous Overlapping Peptides technology. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over 500 million people affected.
Anergis' lead-product AllerT, a vaccine to treat birch pollen allergies, is in Phase II clinical development. AllerR, its second vaccine candidate for the treatment of patients with allergy to ragweed pollen, has recently reached important preclinical milestones and in 2012 received positive feedback from the U.S. FDA for the subsequent clinical development program. Anergis has raised over CHF 22 million from Renaissance PME-Vinci Capital, Sunstone Capital, BioMedInvest and other investors including Esperante Ventures and Defi Gestion.
About Anergis´ Contiguous Overlapping Peptides Technology (COPs)
The only curative therapy of allergies available today, known as "desensitization" or "Specific Immunotherapy" (SIT), is a process of induction of tolerance to the allergen requiring 3-5 years of treatment and exposing patients to the risk of serious side effects. With its ultra-fast desensitization, Anergis has developed the future of allergy treatments. Anergis' vaccines are based on COPs (Contiguous Overlapping Peptides), which reproduce the complete amino acid sequence of the allergen in separate synthetic long peptides. COPs provide the complete allergen sequence covering all T cell epitopes, but do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. This allows for desensitization in 2 months vs. 3 years. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long term immune memory).
Vincent Charlon, CEO
Dr. Ludger Wess, Ines Regina Buth
Tel. +49 40 88165964 or +49 30 2363 2768
Help employers find you! Check out all the jobs and post your resume.
comments powered by